Repurposing metabolic drugs as anti-inflammatory agents
Trends in Endocrinology & Metabolism · 2026-04 · 37 (4) · 313-327
DOI: 10.1016/j.tem.2025.07.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2026-04. Verfasst von Andrew E Hogan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland. Electronic address: Andrew.E.Hogan@mu.ie. Hauptthemen laut MEDLINE: Drug Repositioning, Anti-Inflammatory Agents, Inflammation, Metabolic Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Board, Medical Research Council.
Abstract (Originalsprache)
Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland. Electronic address: Andrew.E.Hogan@mu.ie.
- St Vincent's University Hospital & University College Dublin, Dublin 4, Ireland.
- Institute of Life Science, Swansea University Medical School, Swansea, UK.
- St Vincent's University Hospital & University College Dublin, Dublin 4, Ireland. Electronic address: info@dosheaendo.ie.
Förderung
- Health Research Board
- Medical Research Council
Zitieren
APA
Hogan, A. E., Davis, C., Jenkins, B. J., Jones, N., & O'Shea, D. (2026). Repurposing metabolic drugs as anti-inflammatory agents. Trends in Endocrinology & Metabolism, 37(4), 313-327. https://doi.org/10.1016/j.tem.2025.07.003
Vancouver
Hogan AE, Davis C, Jenkins BJ, Jones N, O'Shea D. Repurposing metabolic drugs as anti-inflammatory agents. Trends in Endocrinology & Metabolism. 2026;37(4):313-327. doi:10.1016/j.tem.2025.07.003
BibTeX
@article{Hogan2026,
author = {Hogan, Andrew E and Davis, Cian and Jenkins, Benjamin J and Jones, Nicholas and O'Shea, Donal},
title = {Repurposing metabolic drugs as anti-inflammatory agents},
journal = {Trends in Endocrinology & Metabolism},
year = {2026},
volume = {37},
number = {4},
pages = {313--327},
doi = {10.1016/j.tem.2025.07.003}
}
EUVIMED